Citations (60)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Anna Viola, Andrea Fontana, Alessandra Belvedere, Riccardo Scoglio, Giuseppe Costantino, Aldo Sitibondo, Marco Muscianisi, Santi Inferrera, Lucia Maria Bruno, Angela Alibrandi, Gianluca Trifirò & Walter Fries. (2020) Diagnostic accuracy of faecal calprotectin in a symptom-based algorithm for early diagnosis of inflammatory bowel disease adjusting for differential verification bias using a Bayesian approach. Scandinavian Journal of Gastroenterology 55:10, pages 1176-1184.
Read now
Read now
Christian Moore. (2018) Response to “Clinical implications of assay-specific differences in f-calprotectin when monitoring inflammatory bowel disease activity over time”. Scandinavian Journal of Gastroenterology 53:3, pages 376-376.
Read now
Read now
Lukasz Kwapisz, Jamie Gregor, Nilesh Chande, Brian Yan, Terry Ponich & Mahmoud Mosli. (2017) The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease. Scandinavian Journal of Gastroenterology 52:8, pages 846-850.
Read now
Read now
Cecilia Högberg, Pontus Karling, Jörgen Rutegård & Mikael Lilja. (2017) Diagnosing colorectal cancer and inflammatory bowel disease in primary care: The usefulness of tests for faecal haemoglobin, faecal calprotectin, anaemia and iron deficiency. A prospective study. Scandinavian Journal of Gastroenterology 52:1, pages 69-75.
Read now
Read now
Natalie E Walsham & Roy A Sherwood. (2016) Fecal calprotectin in inflammatory bowel disease. Clinical and Experimental Gastroenterology 9, pages 21-29.
Read now
Read now
Michael Wagner, Klas Sjöberg, Lina Vigren, Martin Olesen, Cecilia Benoni, Ervin Toth & Marie Carlson. (2016) Elevated fecal levels of eosinophil granule proteins predict collagenous colitis in patients referred to colonoscopy due to chronic non-bloody diarrhea. Scandinavian Journal of Gastroenterology 51:7, pages 835-841.
Read now
Read now
Paul A. S. Olsen, Reidar Fossmark & Gunnar Qvigstad. (2015) Fecal calprotectin in patients with suspected small bowel disease – a selection tool for small bowel capsule endoscopy?. Scandinavian Journal of Gastroenterology 50:3, pages 272-277.
Read now
Read now
Taina Sipponen & Kaija-Leena Kolho. (2015) Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease. Scandinavian Journal of Gastroenterology 50:1, pages 74-80.
Read now
Read now
Emanuel Burri & Christoph Beglinger. (2014) The use of fecal calprotectin as a biomarker in gastrointestinal disease. Expert Review of Gastroenterology & Hepatology 8:2, pages 197-210.
Read now
Read now
Articles from other publishers (51)
Zlatica Rendek, Magnus Falk, Ewa Grodzinsky, Stergios Kechagias & Henrik Hjortswang. (2023) Diagnostic value of fecal calprotectin in primary care patients with gastrointestinal symptoms: A retrospective Swedish cohort study. JGH Open 7:10, pages 708-716.
Crossref
Crossref
Abdulaziz S Asiri, Saad S Algarni, Anood Q Althubaiti, Mohammed A Alzubaidi, Jamal A Alghamdi & Ghazi A Almalki. (2023) Fecal Calprotectin and Organic Gastrointestinal Disease: A Systematic Review. Cureus.
Crossref
Crossref
Fiona A. Ross, James H. Park, David Mansouri, Emilie Combet, Paul G. Horgan, Donald C. McMillan & Campbell S. D. Roxburgh. (2022) The role of faecal calprotectin in diagnosis and staging of colorectal neoplasia: a systematic review and meta-analysis. BMC Gastroenterology 22:1.
Crossref
Crossref
Karoline Freeman, Brian H. Willis, Ronan Ryan, Sian Taylor-Phillips & Aileen Clarke. (2022) Comparing outcomes from tailored meta-analysis with outcomes from a setting specific test accuracy study using routine data of faecal calprotectin testing for inflammatory bowel disease. BMC Medical Research Methodology 22:1.
Crossref
Crossref
Polychronis Pavlidis, Deepak Joshi, Yasser El Sherif, Ben Warner, Shraddha Gulati, James Alexander, Gemma Cross, Tracy Dew, Hadil Abu Arqoub, John Devlin, Michael Heneghan, Patrick Dubois, Ingvar Bjarnason, Nick Powell & Bu'Hussain Hayee. (2022) Faecal calprotectin is a surrogate marker of biliary inflammation in primary sclerosing cholangitis associated inflammatory bowel disease. Frontline Gastroenterology 13:6, pages 497-502.
Crossref
Crossref
Alex Barnes, Paul Spizzo & Réme Mountifield. (2022) Inpatient usage of faecal calprotectin in a tertiary hospital. Internal Medicine Journal 52:3, pages 436-439.
Crossref
Crossref
Jean Jacques WyndaeleJean Jacques Wyndaele. 2022. Sensation in the Pelvic Region. Sensation in the Pelvic Region
79
90
.
Gujjarlapudi Deepika, Namburu Veeraiah, Syed Hassan Naveed & D. Nageshwar Reddy. (2021) Fecal Calprotectin as early predictor for screening and relapse in pediatric chronic diarrhea in India. IP International Journal of Medical Paediatrics and Oncology 7:4, pages 178-184.
Crossref
Crossref
Karoline Freeman, Ronan Ryan, Nicholas Parsons, Sian Taylor-Phillips, Brian H Willis & Aileen Clarke. (2021) Faecal calprotectin testing in UK general practice: a retrospective cohort study using The Health Improvement Network database. British Journal of General Practice 71:712, pages e854-e861.
Crossref
Crossref
Fabio Corsi, Luca Sorrentino, Sara Albasini, Francesco Colombo, Maria Cigognini, Alessandro Massari, Carlo Morasso, Serena Mazzucchelli, Francesca Piccotti, Sandro Ardizzone, Gianluca M. Sampietro & Marta Truffi. (2021) Circulating Fibroblast Activation Protein as Potential Biomarker in Patients With Inflammatory Bowel Disease. Frontiers in Medicine 8.
Crossref
Crossref
Rachel Campbell. (2021) Nurse-led development of a rapid-access clinic and referral pathway for suspected inflammatory bowel disease. Gastrointestinal Nursing 19:2, pages 28-34.
Crossref
Crossref
Anne Line Engsbro, Luise M. Begtrup, Peter Haastrup, Maria Munch Storsveen, Peter Bytzer, Jens Kjeldsen, Ove Schaffalitzky De Muckadell & Dorte Ejg Jarbøl. (2020) A positive diagnostic strategy is safe and saves endoscopies in patients with irritable bowel syndrome: A five‐year follow‐up of a randomized controlled trial. Neurogastroenterology & Motility 33:3.
Crossref
Crossref
Karoline Freeman, Sian Taylor-Phillips, Brian H Willis, Ronan Ryan & Aileen Clarke. (2021) Test accuracy of faecal calprotectin for inflammatory bowel disease in UK primary care: a retrospective cohort study of the THIN data. BMJ Open 11:2, pages e044177.
Crossref
Crossref
Carlo Morasso, Marta Truffi, Renzo Vanna, Sara Albasini, Serena Mazzucchelli, Francesco Colombo, Luca Sorrentino, Gianluca Sampietro, Sandro Ardizzone & Fabio Corsi. (2020) Raman Analysis Reveals Biochemical Differences in Plasma of Crohn’s Disease Patients. Journal of Crohn's and Colitis 14:11, pages 1572-1580.
Crossref
Crossref
Gareth J Walker, Neil Chanchlani, Amanda Thomas, Simeng Lin, Lucy Moore, Neel M Heerasing, Peter Hendy, Mohamed Abdelrahim, Sean Mole, Mandy H Perry, Timothy J Mcdonald, Claire M Bewshea, James W Hart, Richard K Russell, Tariq Ahmad, James R Goodhand & Nicholas A Kennedy. (2020) Primary care faecal calprotectin testing in children with suspected inflammatory bowel disease: a diagnostic accuracy study. Archives of Disease in Childhood 105:10, pages 957-963.
Crossref
Crossref
Els Van de VijverAnke HeidaSolomon IoannouStephanie Van BiervlietThalia HummelZehre YukselGieneke Gonera-de Jong, Renate Schulenberg, Anneke Muller Kobold, Henkjan J. VerkadePatrick F. van Rheenen. (2020) Test Strategies to Predict Inflammatory Bowel Disease Among Children With Nonbloody Diarrhea. Pediatrics 146:2.
Crossref
Crossref
Rafael González-Moret, Ausias Cebolla, Xavier Cortés, Rosa M. Baños, Jaime Navarrete, José Enrique de la Rubia, Juan Francisco Lisón & José Miguel Soria. (2020) The effect of a mindfulness-based therapy on different biomarkers among patients with inflammatory bowel disease: a randomised controlled trial. Scientific Reports 10:1.
Crossref
Crossref
Fernando Bermejo, Alicia Algaba, Daniel Bonillo, Laura Jiménez, Antonio Guardiola-Arévalo, María Pacheco, Ángel Castaño & Iván Guerra. (2020) Limitaciones de la determinación de calprotectina fecal en pacientes con colitis ulcerosa y pólipos inflamatorios. Gastroenterología y Hepatología 43:2, pages 73-78.
Crossref
Crossref
Fernando Bermejo, Alicia Algaba, Daniel Bonillo, Laura Jiménez, Antonio Guardiola-Arévalo, María Pacheco, Ángel Castaño & Iván Guerra. (2020) Limitations of the determination of faecal calprotectin in patients with ulcerative colitis and inflammatory polyps. Gastroenterología y Hepatología (English Edition) 43:2, pages 73-78.
Crossref
Crossref
Christopher Andrew Lamb, Nicholas A Kennedy, Tim Raine, Philip Anthony Hendy, Philip J Smith, Jimmy K Limdi, Bu’Hussain Hayee, Miranda C E Lomer, Gareth C Parkes, Christian Selinger, Kevin J Barrett, R Justin Davies, Cathy Bennett, Stuart Gittens, Malcolm G Dunlop, Omar Faiz, Aileen Fraser, Vikki Garrick, Paul D Johnston, Miles Parkes, Jeremy Sanderson, Helen Terry, Daniel R Gaya, Tariq H Iqbal, Stuart A Taylor, Melissa Smith, Matthew Brookes, Richard Hansen & A Barney Hawthorne. (2019) British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 68:Suppl 3, pages s1-s106.
Crossref
Crossref
Corinne Chmiel, Oliver Senn, Susann Hasler, Thomas Rosemann, Gerhard Rogler, Nadine Zahnd, Ryan Tandjung, Nathalie Scherz, Michael Christian Sulz & Stephan Vavricka. (2019) Can the CalproQuest predict a positive Calprotectin test? A prospective diagnostic study. PLOS ONE 14:11, pages e0224961.
Crossref
Crossref
Yoon‐Kyo An, David Prince, Fergus Gardiner, Teresa Neeman, Ecushla C Linedale, Jane M Andrews, Susan Connor & Jakob Begun. (2019) Faecal calprotectin testing for identifying patients with organic gastrointestinal disease: systematic review and meta‐analysis. Medical Journal of Australia 211:10, pages 461-467.
Crossref
Crossref
Pawel Petryszyn, Aleksandra Staniak, Agnieszka Wolosianska & Pawel Ekk-Cierniakowski. (2019) Faecal calprotectin as a diagnostic marker of inflammatory bowel disease in patients with gastrointestinal symptoms: meta-analysis. European Journal of Gastroenterology & Hepatology 31:11, pages 1306-1312.
Crossref
Crossref
Honghui Zhou & Diane R. MouldReena Khanna & Brian G. Feagan. 2019. Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune‐Mediated Inflammatory Diseases. Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune‐Mediated Inflammatory Diseases
25
42
.
Karoline Freeman, Brian H Willis, Hannah Fraser, Sian Taylor-Phillips & Aileen Clarke. (2019) Faecal calprotectin to detect inflammatory bowel disease: a systematic review and exploratory meta-analysis of test accuracy. BMJ Open 9:3, pages e027428.
Crossref
Crossref
Corinne Chmiel, Stephan R. Vavricka, Susann Hasler, Gerhard Rogler, Nadine Zahnd, Salomé Schiesser, Ryan Tandjung, Nathalie Scherz, Thomas Rosemann & Oliver Senn. (2018) Feasibility of an 8‐item questionnaire for early diagnosis of inflammatory bowel disease in primary care. Journal of Evaluation in Clinical Practice 25:1, pages 155-162.
Crossref
Crossref
Satwik Motaganahalli, Lauren Beswick, Danny Con & Daniel R. van Langenberg. (2019) Faecal calprotectin delivers on convenience, cost reduction and clinical decision‐making in inflammatory bowel disease: a real‐world cohort study. Internal Medicine Journal 49:1, pages 94-100.
Crossref
Crossref
N A Fadeeva, I A Korneeva, O V Knyazev & A I Parfenov. (2018) Biomarkers of inflammatory bowel disease activity. Terapevticheskii arkhiv 90:12, pages 107-111.
Crossref
Crossref
Andrea Padoan, Renata D’Incà, Maria Luisa Scapellato, Rudi De Bastiani, Roberta Caccaro, Claudia Mescoli, Stefania Moz, Dania Bozzato, Carlo-Federico Zambon, Greta Lorenzon, Massimo Rugge, Mario Plebani & Daniela Basso. (2018) Improving IBD diagnosis and monitoring by understanding preanalytical, analytical and biological fecal calprotectin variability. Clinical Chemistry and Laboratory Medicine (CCLM) 56:11, pages 1926-1935.
Crossref
Crossref
James Turvill, Daniel Turnock, Hayden Holmes, Alison Jones, Eleanor Mclaughlan, Victoria Hilton & Stacey Marriott. (2018) Evaluation of the clinical and cost-effectiveness of the York Faecal Calprotectin Care Pathway. Frontline Gastroenterology 9:4, pages 285-294.
Crossref
Crossref
Maria Gloria Mumolo, Lorenzo Bertani, Linda Ceccarelli, Gabriella Laino, Giorgia Di Fluri, Eleonora Albano, Gherardo Tapete & Francesco Costa. (2018) From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting. World Journal of Gastroenterology 24:33, pages 3681-3694.
Crossref
Crossref
Samantha Conroy, Melissa F Hale, Simon S Cross, Kirsty Swallow, Reena H Sidhu, Ravishankar Sargur & Alan J Lobo. (2018) Unrestricted faecal calprotectin testing performs poorly in the diagnosis of inflammatory bowel disease in patients in primary care. Journal of Clinical Pathology 71:4, pages 316-322.
Crossref
Crossref
G. J. Walker, L. Moore, N. Heerasing, P. Hendy, M. H. Perry, T. J. McDonald, T. Debenham, R. Bethune, C. Bewshea, C. Hyde, G. A. Heap, A. Singh, C. Calvert, N. A. Kennedy, J. R. Goodhand & T. Ahmad. (2018) Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study. Alimentary Pharmacology & Therapeutics 47:8, pages 1103-1116.
Crossref
Crossref
Maria Elena Lozoya Angulo, Ignacio de las Heras Gómez, Miriam Martinez Villanueva, Jose Antonio Noguera Velasco & Francisco Avilés Plaza. (2017) Calprotectina fecal, marcador eficaz en la diferenciación de enfermedades inflamatorias intestinales y trastornos funcionales gastrointestinales. Gastroenterología y Hepatología 40:3, pages 125-131.
Crossref
Crossref
Maria Elena Lozoya Angulo, Ignacio de las Heras Gómez, Miriam Martinez Villanueva, Jose Antonio Noguera Velasco & Francisco Avilés Plaza. (2017) Faecal calprotectin, an useful marker in discriminating between inflammatory bowel disease and functional gastrointestinal disorders. Gastroenterología y Hepatología (English Edition) 40:3, pages 125-131.
Crossref
Crossref
Hana Manceau, Valérie Chicha-Cattoir, Hervé Puy & Katell Peoc’h. (2017) Fecal calprotectin in inflammatory bowel diseases: update and perspectives. Clinical Chemistry and Laboratory Medicine (CCLM) 55:4.
Crossref
Crossref
Khadija H. Chaudrey & Edward V. LoftusJr.Jr.. 2017. Inflammatory Bowel Disease. Inflammatory Bowel Disease
45
59
.
Sjoerd G. Elias, Liselotte Kok, Niek J. de Wit, Ben J. M Witteman, Jelle G. Goedhard, Mariëlle J. L. Romberg-Camps, Jean W. M. Muris & Karel G. M. Moons. (2016) Is there an added value of faecal calprotectin and haemoglobin in the diagnostic work-up for primary care patients suspected of significant colorectal disease? A cross-sectional diagnostic study. BMC Medicine 14:1.
Crossref
Crossref
Marianne Williams, Yvonne Barclay, Rosie Benneyworth, Steve Gore, Zoe Hamilton, Rudi Matull, Iain Phillips, Leah Seamark, Kate Staveley, Steve Thole & Emma Greig. (2016) Using best practice to create a pathway to improve management of irritable bowel syndrome: aiming for timely diagnosis, effective treatment and equitable care. Frontline Gastroenterology 7:4, pages 323-330.
Crossref
Crossref
Craig Mowat, Jayne Digby, Judith A Strachan, Robyn Wilson, Francis A Carey, Callum G Fraser & Robert J C Steele. (2016) Faecal haemoglobin and faecal calprotectin as indicators of bowel disease in patients presenting to primary care with bowel symptoms. Gut 65:9, pages 1463-1469.
Crossref
Crossref
Anet A. Soubières & Andrew Poullis. (2016) Emerging Biomarkers for the Diagnosis and Monitoring of Inflammatory Bowel Diseases. Inflammatory Bowel Diseases 22:8, pages 2016-2022.
Crossref
Crossref
James Turvill, Assad Aghahoseini, Nala Sivarajasingham, Kazim Abbas, Murtaza Choudhry, Kostantinos Polyzois, Kostantinos Lasithiotakis, Dimitra Volanaki, Baek Kim, Fiona Langlands, Helen Andrew, Jesper Roos, Samantha Mellen, Daniel Turnock & Alison Jones. (2016) Faecal calprotectin in patients with suspected colorectal cancer: a diagnostic accuracy study. British Journal of General Practice 66:648, pages e499-e506.
Crossref
Crossref
Anet A Soubières. (2016) Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease. World Journal of Gastrointestinal Pharmacology and Therapeutics 7:1, pages 41.
Crossref
Crossref
Ching Lam, Wei Tan, Matthew Leighton, Margaret Hastings, Melanie Lingaya, Yirga Falcone, Xiaoying Zhou, Luting Xu, Peter Whorwell, Andrew F Walls, Abed Zaitoun, Alan Montgomery & Robin Spiller. (2016) A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D). Gut 65:1, pages 91-99.
Crossref
Crossref
Ching Lam, Wei Tan, Matthew Leighton, Margaret Hastings, Melanie Lingaya, Yirga Falcone, Xiaoying Zhou, Luting Xu, Peter Whorwell, Andrew F Walls, Abed Zaitoun, Alan Montgomery & Robin C Spiller. (2015) Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): a multicentre, parallel-group, randomised placebo-controlled trial. Efficacy and Mechanism Evaluation 2:2, pages 1-62.
Crossref
Crossref
Lorete Maria da Silva KOTZE, Renato Mitsunori NISIHARA, Sandra Beatriz MARION, Murilo Franco CAVASSANI & Paulo Gustavo KOTZE. (2015) FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms. Arquivos de Gastroenterologia 52:1, pages 50-54.
Crossref
Crossref
Shannon Chang. (2015) Disease monitoring in inflammatory bowel disease. World Journal of Gastroenterology 21:40, pages 11246.
Crossref
Crossref
M. Camilleri, A. Shin, I. Busciglio, P. Carlson, A. Acosta, A. E. Bharucha, D. Burton, J. Lamsam, A. Lueke, L. J. Donato & A. R. Zinsmeister. (2014) Validating biomarkers of treatable mechanisms in irritable bowel syndrome. Neurogastroenterology & Motility 26:12, pages 1677-1685.
Crossref
Crossref
Geir Larsson, Koticherry Thrivikrama Shenoy, Ramalingom Ramasubramanian, Lakshmikanthan Thayumanavan, Leena Kondarappassery Balakumaran, Gunnar A Bjune & Bjørn A Moum. (2014) Faecal calprotectin levels differentiate intestinal from pulmonary tuberculosis: An observational study from Southern India. United European Gastroenterology Journal 2:5, pages 397-405.
Crossref
Crossref
Emily K. Wright, Peter De Cruz, Richard Gearry, Andrew S. Day & Michael A. Kamm. (2014) Fecal Biomarkers in the Diagnosis and Monitoring of Crohnʼs Disease. Inflammatory Bowel Diseases 20:9, pages 1668-1677.
Crossref
Crossref
Uri Kopylov, Greg Rosenfeld, Brian Bressler & Ernest Seidman. (2014) Clinical Utility of Fecal Biomarkers for the Diagnosis and Management of Inflammatory Bowel Disease. Inflammatory Bowel Diseases 20:4, pages 742-756.
Crossref
Crossref